Protagonist Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PTGX$135.90+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||||
| · 2023 · 2022 · 2021 | |||||||||
| Net loss | | $(78,955) | | $(127,393) | | $(125,551) | |||
| Other comprehensive loss: | | | | | | | | ||
| Gain (loss) on translation of foreign operations | | 194 | | (149) | | (182) | |||
| Unrealized gain (loss) on marketable securities | | 60 | | 89 | | (145) | |||
| Comprehensive loss | | $(78,701) | | $(127,453) | | $(125,878) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.